(3R,4R)-1-(4-fluorophenyl)-3-[(4-fluorobenzoyl)methylthio]-4-{4-[N-(carboxymethyl)carbamoylmethoxy]phenyl}azetidin-2-one | 858104-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (3R,4R)-1-(4-fluorophenyl)-3-[(4-fluorobenzoyl)methylthio]-4-{4-[N-(carboxymethyl)carbamoylmethoxy]phenyl}azetidin-2-one
• 英文别名: N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycine；N-{[4-((2R,3R)-1-(4-Fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio)-4-oxoazetidin-2-yl)phenoxy]acetyl}glycine；2-[[2-[4-[(2R,3R)-1-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethyl]sulfanyl-4-oxoazetidin-2-yl]phenoxy]acetyl]amino]acetic acid
• CAS: 858104-55-9
• 化学式: C₂₇H₂₂F₂N₂O₆S
• 分子量: 540.544
• InChiKey: FSRBLUMWQIIGMZ-CLJLJLNGSA-N

物化性质

• 沸点：
  889.6±65.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  9

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(4-{(2R,3R)-1-(4-fluoro-phenyl)-3-[(RS)-2-(4-fluoro-phenyl)-2-oxoethylsulfanyl]-4-oxo-azetidin-2-yl}-phenoxy)-acetic acid	858104-50-4	C25H19F2NO5S	483.492
  ——	[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-methoxyphenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetic acid	858104-20-8	C26H22FNO6S	495.528
  ——	(3R,4R)-1-(4-fluorophenyl)-3-(4-methoxybenzylsulphanyl)-4-[4-(t-butoxycarbonylmethoxy)phenyl]azetidin-2-one	858104-47-9	C29H30FNO5S	523.625
  ——	(3R,4R)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-[4-(t-butoxycarbonylmethoxy)phenyl]azetidin-2-one	858104-48-0	C26H24FN3O6S2	557.623
  ——	tert-butyl (4-{(1R)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl}phenoxy)acetate	858104-46-8	C38H39FN2O7S	686.801

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}-L-alanine	858104-02-6	C28H24F2N2O6S	554.571
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-D-valine	858103-95-4	C32H31F2N3O7S	639.677
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-L-asparagine	858103-97-6	C31H28F2N4O8S	654.648
  ——	2-[[2-[[2-[4-[(2R,3R)-1-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethyl]sulfanyl-4-oxoazetidin-2-yl]phenoxy]acetyl]amino]acetyl]amino]-4,4-dimethylpentanoic acid	1033706-45-4	C34H35F2N3O7S	667.731
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-3-(trimethylsilyl)alanine	——	C33H37F2N3O7SSi	685.821
  ——	N-({4-[(2R,3R)-1-(4-fluorophenyl)-3-{[(2RS)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine	858103-14-7	C32H33F2N3O7S	641.693
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[(2RS)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-3-methyl-D-valine	858103-63-6	C33H35F2N3O7S	655.72
  ——	N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-3-cyclohexyl-D-alanine	858103-29-4	C36H39F2N3O7S	695.784
  ——	Azd-4121	1369489-34-8	C36H39F2N3O7S	695.784

反应信息

• 作为反应物：
  描述：

  (3R,4R)-1-(4-fluorophenyl)-3-[(4-fluorobenzoyl)methylthio]-4-{4-[N-(carboxymethyl)carbamoylmethoxy]phenyl}azetidin-2-one 在 N-甲基吗啉 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.17h， 生成
  参考文献：
  名称：

  WO2006/137795

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-甲酰基苯氧基)乙酸甲酯 在 N-甲基吗啉 、 titanium(IV) isopropylate 、 甲酸 、 N,O-双三甲硅基乙酰胺 、 四氯化钛 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 lithium chloride 作用下， 以 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 63.5h， 生成 (3R,4R)-1-(4-fluorophenyl)-3-[(4-fluorobenzoyl)methylthio]-4-{4-[N-(carboxymethyl)carbamoylmethoxy]phenyl}azetidin-2-one
  参考文献：
  名称：

  Selection and Development of a Route for Cholesterol Absorption Inhibitor AZD4121

  摘要：

  The development of a synthetic route to the cholesterol absorption inhibitor AZD4121 is presented. Key steps are a highly enantioselective CBS reduction, a stereospecific Staudinger reaction, an amine/lithium chloride mediated ester hydrolysis, and a resolution of a 50:50 diastereomeric mixture by recrystallization. The synthesis was accomplished in 10 linear steps, and the overall yield, when compared with the lead optimization (LO) route, was improved from 1% to 20%. All purifications of intermediates through preparative HPLC or silica gel chromatography were avoided. This was possible since many of the intermediates along the route could be used as such in the next step until an intermediate with suitable crystalline properties could be identified and purified through crystallization.

  DOI：

  10.1021/op200314z

文献信息

• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
• Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
  申请人：Alenfalk Susanne

  公开号：US20080064676A1

  公开（公告）日：2008-03-13

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团如定义所示），其药学上可接受的盐、此类盐的溶剂化合物、其前药以及其作为治疗高脂血症的胆固醇吸收抑制剂的用途。本文还描述了其制造工艺和含有它们的制药组合物。
• Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia
  申请人：Alenfalk Susanne

  公开号：US20100216759A1

  公开（公告）日：2010-08-26

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团如定义），其药学上可接受的盐、盐的溶剂、这种盐的溶剂和其前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途。本文还描述了它们的制造过程和包含它们的制药组合物。
• Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07871998B2

  公开（公告）日：2011-01-18

  Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式（I）的化合物：（其中变量基团的定义如下）药学上可接受的盐，其溶剂化物，这些盐的溶剂化物及其前药，并将其用作胆固醇吸收抑制剂，用于治疗高脂血症。还描述了它们的制造过程和含有它们的制药组合物。
• Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
  申请人：Dahlstrom Mikael

  公开号：US20100168075A1

  公开（公告）日：2010-07-01

  The application relates to novel 2-azetidinone derivatives of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors and are useful in the treatment of hyperlipidaemic conditions, including atherosclerosis, Alzheimers' disease and cholesterol associated tumours. The application also relates to pharmaceutical formulations comprising such compounds and to processes for their preparation.

  该申请涉及公式（I）的新型2-氮杂环己酮衍生物及其药学上可接受的盐、溶剂和前药。这些化合物是胆固醇吸收抑制剂，可用于治疗高脂血症状况，包括动脉硬化、阿尔茨海默病和胆固醇相关肿瘤。该申请还涉及包含这些化合物的制药配方以及它们的制备过程。